Author

Rajiv Mundayat 1

1 Pfizer Inc,New York,United States

AN UPDATE ON THE ANALYSIS OF NON-MELANOMA SKIN CANCER IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME AS OF MAY 2019

Bruce E. Sands, Walter Reinisch, Julian Panés, Paulo Gustavo Kotze, Donna T Judd, Rajiv Mundayat, Nervin Lawendy

ANALYSIS OF INFECTIONS OF INTEREST IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME

Alessandro Armuzzi, Christina Ha, Michael Chiorean, Nervin Lawendy, Rajiv Mundayat, Leonardo Salese, John C. Woolcott, Chinyu Su, Iris Dotan

ASSOCIATION BETWEEN DURATION OF LATEST FLARE BEFORE INDUCTION TREATMENT WITH TOFACITINIB AND EFFICACY OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS

Geert D’Haens, Alessandro Armuzzi, Chinyu Su, Xiang Guo, Irene Modesto, Rajiv Mundayat, David P. Hudesman, Michael Chiorean

ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIOR DURATION OF REMISSION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY (BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY

Marla C. Dubinsky, Geert R. D'Haens, William J. Sandborn, Julian Panés, Chinyu Su, Nervin Lawendy, Irina Lazariciu, Sean Gardiner, Rajiv Mundayat, nicole kulisek, Irene Modesto, Siew C. Ng, Joana Torres

HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB: AN UPDATE AS OF MAY 2019

Kevin L. Winthrop, Gil Y. Melmed, Severine Vermeire, Nervin Lawendy, Rajiv Mundayat, nicole kulisek, Chinyu Su

HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB: RESULTS FROM THE PHASE 2 AND PHASE 3 CLINICAL PROGRAMMES

Kevin L. Winthrop, Severine Vermeire, Julian Panés, Gil Y. Melmed, nicole kulisek, Rajiv Mundayat, Nervin Lawendy, Chinyu Su

IMPACT OF PRIOR TUMOUR NECROSIS FACTOR INHIBITOR FAILURE AND PRIOR CORTICOSTEROID USE ON THE MAINTENANCE OF EFFICACY OF TOFACITINIB FOLLOWING DOSE REDUCTION IN PATIENTS WITH ULCERATIVE COLITIS WHO WERE IN STABLE REMISSION: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY

Marla C. Dubinsky, William J. Sandborn, Sean Gardiner, Rajiv Mundayat, Irene Modesto, Jerome Paulissen, Severine Vermeire, Paulo Kotze, Chinyu Su, Nervin Lawendy, nicole kulisek, Geert D’Haens, Joana Torres

MAINTENANCE OF REMISSION WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: FINAL RESULTS OF A SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL, LONG-TERM EXTENSION STUDY, OCTAVE OPEN

Walter Reinisch, Jean-Frédéric Colombel, Mark T. Osterman, Patricio Ibáñez, Severine Vermeire, Peter Irving, Susan B. Connelly, Rajiv Mundayat, Nervin Lawendy, Sean Gardiner, Chinyu Su

NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY

Geert R. D'Haens, Genoile O. Santana, William J. Sandborn, Irene Modesto, Chinyu Su, Nervin Lawendy, Jerome Paulissen, Marla C. Dubinsky, Miguel Regueiro, nicole kulisek, Sean Gardiner, Rajiv Mundayat, Joana Torres

PATIENT-REPORTED OUTCOME IMPROVEMENT WITH TOFACITINIB IN THE ULCERATIVE COLITIS OCTAVE CLINICAL PROGRAMME

Mahmoud Mosli, David P. Hudesman, Joana Torres, Leonardo Salese, John C. Woolcott, Rajiv Mundayat, Chinyu Su, Jessica Allegretti

Item 1 - 10 / 15
1
2